Answer
Patients with MPS VII receiving vestronidase alfa should be monitored for neck or back pain, limb weakness, changes in reflexes, or urinary and faecal incontinence as signs of spinal cord compression or neck instability, with appropriate clinical treatment sought immediately.
Sources for this answer
- Mepsevii 2 mg/mL concentrate for solution for infusionUltragenyx UK · emc · SmPC §4.4 Special warnings and precautions for use · Version 1Document updated
Sources checked